Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (251-260 of 319) with videos related to

Pageof 32
Sort By:
Cancer Treatment Reviews|May 19, 2010
Metastasis and bone loss: advancing treatment and preventionRobert E Coleman, Allan Lipton, G David Roodman, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
European Urology|May 11, 2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer CohortMatthew R Smith, Emmanuel S Antonarakis, Charles J Ryan, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2021
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trialMatthew R Smith, Neal Shore, Teuvo L Tammela, et al.
Prostate Cancer and Prostatic Diseases|August 24, 2023
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Redox Biology|April 27, 2018
Integrative metabolomics and transcriptomics signatures of clinical tolerance to Plasmodium vivax reveal activation of innate cell immunity and T cell signalingLuiz G Gardinassi, Myriam Arévalo-Herrera, Sócrates Herrera, et al.
European Urology|July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Johann S de Bono, Matthew R Smith, Fred Saad, et al.
Pageof 32

Showing results (251-260 of 319) with videos related to

Sort By:
Pageof 32
Cancer Treatment Reviews|May 19, 2010
Metastasis and bone loss: advancing treatment and preventionRobert E Coleman, Allan Lipton, G David Roodman, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
JAMA Oncology|June 3, 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Shibu Thomas, Fred Saad, et al.
European Urology|May 11, 2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer CohortMatthew R Smith, Emmanuel S Antonarakis, Charles J Ryan, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2022
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2021
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trialMatthew R Smith, Neal Shore, Teuvo L Tammela, et al.
Prostate Cancer and Prostatic Diseases|August 24, 2023
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamideYaoYao Pollock, Matthew R Smith, Fred Saad, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Redox Biology|April 27, 2018
Integrative metabolomics and transcriptomics signatures of clinical tolerance to Plasmodium vivax reveal activation of innate cell immunity and T cell signalingLuiz G Gardinassi, Myriam Arévalo-Herrera, Sócrates Herrera, et al.
European Urology|July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Johann S de Bono, Matthew R Smith, Fred Saad, et al.
Pageof 32